452 related articles for article (PubMed ID: 31973017)
1. Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms.
Ho JK; Jeevan-Raj B; Netter HJ
Viruses; 2020 Jan; 12(2):. PubMed ID: 31973017
[No Abstract] [Full Text] [Related]
2. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
Vietheer PT; Boo I; Drummer HE; Netter HJ
Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
[TBL] [Abstract][Full Text] [Related]
3. Chimeric hepatitis B virus (HBV)/hepatitis C virus (HCV) subviral envelope particles induce efficient anti-HCV antibody production in animals pre-immunized with HBV vaccine.
Beaumont E; Roingeard P
Vaccine; 2015 Feb; 33(8):973-6. PubMed ID: 25596457
[TBL] [Abstract][Full Text] [Related]
4. Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity.
Hyakumura M; Walsh R; Thaysen-Andersen M; Kingston NJ; La M; Lu L; Lovrecz G; Packer NH; Locarnini S; Netter HJ
J Virol; 2015 Nov; 89(22):11312-22. PubMed ID: 26339047
[TBL] [Abstract][Full Text] [Related]
5. Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine.
Beaumont E; Patient R; Hourioux C; Dimier-Poisson I; Roingeard P
Hepatology; 2013 Apr; 57(4):1303-13. PubMed ID: 23150224
[TBL] [Abstract][Full Text] [Related]
6. Neutralization effects of antibody elicited by chimeric HBV S antigen viral-like particles presenting HCV neutralization epitopes.
Wei S; Lei Y; Yang J; Wang X; Shu F; Wei X; Lin F; Li B; Cui Y; Zhang H; Wei S
Vaccine; 2018 Apr; 36(17):2273-2281. PubMed ID: 29576303
[TBL] [Abstract][Full Text] [Related]
7. Glycoengineered hepatitis B virus-like particles with enhanced immunogenicity.
Joe CCD; Chatterjee S; Lovrecz G; Adams TE; Thaysen-Andersen M; Walsh R; Locarnini SA; Smooker P; Netter HJ
Vaccine; 2020 May; 38(22):3892-3901. PubMed ID: 32284273
[TBL] [Abstract][Full Text] [Related]
8. Development, Production, and Characterization of Hepatitis B Subviral Envelope Particles as a Third-Generation Vaccine.
Battagliotti JM; Fontana D; Etcheverrigaray M; Kratje R; Prieto C
Methods Mol Biol; 2022; 2410():273-287. PubMed ID: 34914052
[TBL] [Abstract][Full Text] [Related]
9. Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.
Reynolds TD; Buonocore L; Rose NF; Rose JK; Robek MD
J Virol; 2015 Oct; 89(20):10407-15. PubMed ID: 26246574
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B virus-like particles expressing Plasmodium falciparum epitopes induce complement-fixing antibodies against the circumsporozoite protein.
Kingston NJ; Kurtovic L; Walsh R; Joe C; Lovrecz G; Locarnini S; Beeson JG; Netter HJ
Vaccine; 2019 Mar; 37(12):1674-1684. PubMed ID: 30773400
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Virus-Like Particles of Prawn Nodavirus Displaying Hepatitis B Virus Immunodominant Region: Biophysical Properties and Cytokine Response.
Ninyio NN; Ho KL; Yong CY; Chee HY; Hamid M; Ong HK; Mariatulqabtiah AR; Tan WS
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672018
[TBL] [Abstract][Full Text] [Related]
12. Mechanism and therapeutic potential of DNA-based immunization against the envelope proteins of hepatitis B virus in normal and transgenic mice.
Oka Y; Akbar SM; Horiike N; Joko K; Onji M
Immunology; 2001 May; 103(1):90-7. PubMed ID: 11380696
[TBL] [Abstract][Full Text] [Related]
13. Subunit, recombinant and synthetic hepatitis B vaccines.
Zuckerman AJ
Scand J Gastroenterol Suppl; 1985; 117():27-38. PubMed ID: 3912963
[TBL] [Abstract][Full Text] [Related]
14. Incorporation of apolipoprotein E into HBV-HCV subviral envelope particles to improve the hepatitis vaccine strategy.
Gomez-Escobar E; Burlaud-Gaillard J; Visdeloup C; Ribeiro E Silva A; Coutant P; Roingeard P; Beaumont E
Sci Rep; 2021 Nov; 11(1):21856. PubMed ID: 34750487
[TBL] [Abstract][Full Text] [Related]
15. Interactions of hepatitis B virus with hepatocytes: mechanism and clinical relevance.
Theilmann L; Goeser T
Hepatogastroenterology; 1991 Feb; 38(1):10-3. PubMed ID: 1709133
[TBL] [Abstract][Full Text] [Related]
16. Characterization of hepatitis B virus surface antigen particles expressed in stably transformed mammalian cell lines containing the large, middle and small surface protein.
Battagliotti JM; Fontana D; Etcheverrigaray M; Kratje R; Prieto C
Antiviral Res; 2020 Nov; 183():104936. PubMed ID: 32979402
[TBL] [Abstract][Full Text] [Related]
17. A novel chimeric Hepatitis B virus S/preS1 antigen produced in mammalian and plant cells elicits stronger humoral and cellular immune response than the standard vaccine-constituent, S protein.
Dobrica MO; Lazar C; Paruch L; Skomedal H; Steen H; Haugslien S; Tucureanu C; Caras I; Onu A; Ciulean S; Branzan A; Clarke JL; Stavaru C; Branza-Nichita N
Antiviral Res; 2017 Aug; 144():256-265. PubMed ID: 28666757
[TBL] [Abstract][Full Text] [Related]
18. Efficient cellular and humoral immune response and production of virus-neutralizing antibodies by the Hepatitis B Virus S/preS1
Pantazica AM; Dobrica MO; Lazar C; Scurtu C; Tucureanu C; Caras I; Ionescu I; Costache A; Onu A; Clarke JL; Stavaru C; Branza-Nichita N
Front Immunol; 2022; 13():941243. PubMed ID: 35935966
[TBL] [Abstract][Full Text] [Related]
19. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2.
Chow YH; Huang WL; Chi WK; Chu YD; Tao MH
J Virol; 1997 Jan; 71(1):169-78. PubMed ID: 8985336
[TBL] [Abstract][Full Text] [Related]
20. [Approaches to developing an optimal vaccine against hepatitis B viruses].
Gerlich WH; Heermann KH; Thomssen R
Immun Infekt; 1988 Oct; 16(5):167-74. PubMed ID: 3061927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
